Posts Tagged Vitaros
-
Apricus Biosciences Strengthens Vitaros(R) and Nexact(R) Patent Estate With Two New Patent Allowances
SAN DIEGO, May 25, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) (http://www.apricusbio.com) announced today that the Canadian Intellectual Property Office issued a Notice of Allowance for a Canadian patent on certain methods of manufacture for the...
-
Apricus Biosciences’ Marketing Application for Vitaros(R), for the Treatment of Erectile Dysfunction, is Accepted for Review in Europe
SAN DIEGO, June 28, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) announced today that its marketing application for Vitaros®, indicated for the treatment of patients with erectile dysfunction ("ED"), has been accepted for review through the European Decentralized...
-
Apricus Biosciences to Present at the Euro-Biotech Partnering Forum 2011 to Further Its Partnership Efforts
SAN DIEGO, May 23, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) (http://www.apricusbio.com) today announced that Linda Smibert, Vice President, Business Development at the Company's NexMed, USA, Inc. subsidiary, will present at the Euro-Biotech Partnering Forum 20...
-
Apricus Biosciences Expands Patent Coverage in Mexico for Its Erectile Dysfunction Drug, Vitaros(R)
SAN DIEGO, March 31, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI), announced today that the Mexican Patent Office ("MPO") will grant an additional patent for Vitaros®, the Company's topical alprostadil-based cream for the treatment of erectile dysfunction ("ED")....
-
Apricus Bio Announces Expansion of Patent Portfolio for Topical Cream to Treat Premature Ejaculation With Issuance of Japanese Patent
SAN DIEGO, Jan. 14, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc., ("Apricus Bio") (Nasdaq:APRI) today announced that the Japanese Patent Office recently issued a Decision to Grant a Patent for the Company's development of a topical cream that utilizes vasoactive prostaglandin E to treat premat...
-
Apricus Biosciences Announces Upcoming Presentations at the 4th Annual OneMedForum San Francisco and the Biotech Showcase 2011
SAN DIEGO, Dec. 13, 2010 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI), announced today that Dr. Bassam Damaj, President and Chief Executive Officer, will provide company overview presentations at two conferences in San Francisco, CA on Wednesday, January 12, 2011, as f...
